This is positive news for the European PA6 market which has been tight since Q4.
Lanxess lifts FM on caprolactam and PA6 after successfully fixing the issues that started at the end of October, according to reliable sources.
The company had suffered defects at its caprolactam plant in Antwerp, Belgium.
And the facility in Uerdingen, Germany, was also impacted, which forced Lanxess to shut down both plants.
It is understood that the company has now fixed the issues and returned to normal level of production at both sites.
Therefore, Lanxess was able to lift force majeure (FM) on both caprolactam and nylon 6 (PA6) compounds.
However, as the company will most likely rebuild stocks amid high demand, supply will remain limited.
The PA6 market has been tight for months.
And prices have been climbing since Q4, also helped by a recovery in benzene prices.
As this tightness continues in February, PA6 prices are expected to increase again.